Adenosine triphosphate (ATP) and aluminium hydroxide composite adjuvant and vaccine containing same

An aluminum hydroxide and adjuvant technology, applied in the field of immunology, can solve the problem that the effect of aluminum adjuvant alone is not ideal, and achieve the effects of improving the level of humoral immune response, reducing the number of immunizations, and simple preparation process

Active Publication Date: 2012-07-04
INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In order to solve the problem that the current aluminum adjuvant used alone is still not ideal, the present invention proposes the idea of ​​using adenosine triphosphate disodium ATP and aluminum hydroxide to prepare a new type of composite adjuvant on the basis of the existing aluminum adjuvant. After a large number of experiments and Creative labor to provide a safe, efficient, stable and economical compound adjuvant

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Adenosine triphosphate (ATP) and aluminium hydroxide composite adjuvant and vaccine containing same
  • Adenosine triphosphate (ATP) and aluminium hydroxide composite adjuvant and vaccine containing same
  • Adenosine triphosphate (ATP) and aluminium hydroxide composite adjuvant and vaccine containing same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] The ATP and aluminum hydroxide composite adjuvant provided by the invention is formed by mixing components in the following mass ratio: ATP:aluminum hydroxide=10:2.7.

[0022] The vaccine containing the compound adjuvant provided by the present invention is formed by adding 1.27 mg of the compound adjuvant to the vaccine of 0.25 IU (100 μL), and the compound adjuvant is composed of the following mass ratio components: ATP: hydrogen Alumina = 10: 2.7. Among them, the aluminum hydroxide is currently commonly used aluminum hydroxide colloidal adjuvant, and its preparation method refers to "Chinese Pharmacopoeia (Part Three)"; the ATP is adenosine triphosphate disodium for injection, purchased from Shanghai First Biochemical Pharmaceutical Co., Ltd. Company; the vaccine is a conventional human rabies vaccine (hamster kidney cells), purchased from Dalian Hanxin Biopharmaceutical Co., Ltd.

[0023] The immunization test and effect that present embodiment is used to prepare g...

Embodiment 2

[0039] The ATP and aluminum hydroxide composite adjuvant provided by the invention is formed by mixing components in the following mass ratio: ATP:aluminum hydroxide=5:2.7.

[0040] The vaccine containing the compound adjuvant provided by the present invention is formed by adding 0.77 mg of the compound adjuvant to the vaccine of 0.25 IU (100 μL), and the compound adjuvant is composed of the following mass ratio components: ATP: hydrogen Aluminum oxide = 5: 2.7. Among them, the aluminum hydroxide is currently commonly used aluminum hydroxide colloidal adjuvant, and its preparation method refers to "Chinese Pharmacopoeia (Part Three)"; the ATP is adenosine triphosphate disodium for injection, purchased from Shanghai First Biochemical Pharmaceutical Co., Ltd. Company; the vaccine is human rabies vaccine (hamster kidney cells), purchased from Dalian Hanxin Biopharmaceutical Co., Ltd.

[0041] The immunization test and effect that present embodiment is used to prepare gained rabi...

Embodiment 3

[0052] The ATP and aluminum hydroxide composite adjuvant provided by the present invention is formed by mixing components in the following mass ratio: ATP:aluminum hydroxide=10:1.8.

[0053] The vaccine containing the compound adjuvant provided by the present invention is formed by adding 1.18 mg of the compound adjuvant to the vaccine of 0.25 IU (100 μL), and the compound adjuvant is composed of the following mass ratio components: ATP: hydrogen Alumina = 10: 1.8. Among them, the aluminum hydroxide is currently commonly used aluminum hydroxide colloidal adjuvant, and its preparation method refers to "Chinese Pharmacopoeia (Part Three)"; the ATP is adenosine triphosphate disodium for injection, purchased from Shanghai First Biochemical Pharmaceutical Co., Ltd. Company; the vaccine is human rabies vaccine (hamster kidney cells), purchased from Dalian Hanxin Biopharmaceutical Co., Ltd.

[0054] The immunization test and effect that present embodiment is used to prepare gained r...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an adenosine triphosphate (ATP) and aluminium hydroxide composite adjuvant and a vaccine containing the same. The composite adjuvant consists of the following components: ATP and aluminium hydroxide, wherein the mass ratio of the ATP to the aluminium hydroxide is equal to (5-10):(1.8-2.7). The vaccine containing the composite adjuvant is prepared by adding 0.68 to 1.27mg ofcomposite adjuvant into per 100 microlitres of vaccine and mixing. The composite adjuvant is high in safety and repeatability and low in cost, and is convenient to prepare; humoral immunity response of antigenic specificity can be well induced, and the induction efficiency and the specific antibody production level are higher than those of an aluminium adjuvant which is independently used in effect; and when the vaccine is used by matching with a rabies vaccine, the humoral immunity response level of the rabies vaccine can be effectively improved, the immunity time of the vaccine can be reduced, and the immune efficiency of the vaccine can be improved.

Description

technical field [0001] The invention relates to a composite adjuvant, in particular to a composite adjuvant of adenosine triphosphate disodium ATP and aluminum hydroxide and a vaccine containing the composite adjuvant, belonging to the technical field of immunology. Background technique [0002] An adjuvant refers to a substance used simultaneously or in advance with an antigen, which can effectively enhance the body's immune response to the antigen or change the type of immune response, but it itself is not immunogenic and cannot act alone to cause an immune response. An ideal adjuvant should have the following characteristics: effectiveness, safety, stability and economy. Currently commonly used adjuvants include aluminum hydroxide, liposomes, Freund's adjuvants, mucosal immune adjuvants, CpG sequences, saponins, cytokines, nanoparticles, and other adjuvants from natural sources, all of which can effectively enhance antigen immunity. However, only aluminum hydroxide adjuv...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39A61K39/205A61P31/14
Inventor 张浩胡云章胡凝珠王海漩
Owner INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap